This article is more than 5 years old. Information may no longer be current.

To the Editor

Issue: October 10, 2019

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In reference to the commentary “No easy answers to address drug shortages,” in the Aug. 25, 2019, issue of Ocular Surgery News, we, HUB Pharmaceuticals USA, would like to offer a correction.

HUB Pharmaceuticals USA is the exclusive U.S. distributor for our indocyanine green (NDC 17238-424-06). We have been the distributor since 2010. Indocyanine green USP is used in ophthalmology for retinal angiography.

HUB Pharmaceuticals has and continues to maintain full stocks of our ICG. We provide the product through our network of ophthalmic distributors nationwide, as well as via the wholesaler distribution channel, including AmerisourceBergen, Cardinal Health and McKesson Drug.

We would appreciate it if this information would be included as a response to this commentary. There have been many rumors as to the availability of some of these products, and we would like to correct the record.

Ron Clarke
Vice President, Sales & Business Development
HUB Pharmaceuticals USA